ARCPOINT ANNOUNCES APPOINTMENT OF PETER KENDALL AS INTERIM CHIEF EXECUTIVE OFFICER

🔗 원문 전체 보기 → Financial Post

요약

GREENVILLE, South Carolina, June 09, 2026 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces that its Board of Directors has appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. M…

본문

This section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Article content

GREENVILLE, South Carolina, June 09, 2026 (GLOBE NEWSWIRE) — ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) announces that its Board of Directors has appointed Peter Kendall as Interim Chief Executive Officer of the Company, effective June 9, 2026. Mr. Kendall’s appointment remains subject to acceptance by the TSX Venture Exchange (the “TSXV” or the “Exchange”), including acceptance of the Exchange’s required Personal Information Form and completion of customary Exchange review and verification procedures.

Sign In or Create an Account

or View more offersArticle content Story continues below This advertisement has not loaded yet, but your article continues below. Article content

In connection with Mr. Kendall’s appointment, John Constantine has stepped down as President and Chief Executive Officer of the Company and will transition to a role focused on supporting the Company’s sales, marketing and commercial development efforts, including the commercial development of the MyARCpointLabs (“MAPL”) technology platform. Mr. Constantine will continue to serve as a director of the Company. The Company’s Board members remain Zelong “Roger” He, David Keys, John Constantine and Adam Ho.

Article contentWe apologize, but this video has failed to load.Try refreshing your browser, or
tap here to see other videos from our team.Article contentTop Stories

Get the latest headlines, breaking news and columns.

By signing up you consent to receive the above newsletter from Postmedia Network Inc.

Thanks for signing up!

A welcome email is on its way. If you don't see it, please check your junk folder.

The next issue of Top Stories will soon be in your inbox.

Interested in more newsletters? Browse here.

Article content

Mr. Kendall’s initial engagement is for a term of 90 days. During this period, Mr. Kendall will work with the Board and management to assess the Company’s business model, MAPL technology platform, commercial relationships, assets and strategic direction, and to provide recommendations to the Board on the best commercial and financial path forward for the Company and its stakeholders.

Article content

“Peter brings healthcare commercialization, strategic partnership and public-company experience that is well aligned with ARCpoint’s current priorities,” said Adam Ho, Chief Financial Officer and a director of ARCpoint. “Our objective for this next phase is to assess how the Company’s MAPL platform, commercial relationships and other assets can be used most effectively, both commercially and financially.”

Article content Story continues below This advertisement has not loaded yet, but your article continues below. Article content

“My mandate over the initial term is to provide the Board with a fresh, fact-based assessment of the Company’s options and a clear recommendation on the commercial path forward,” said Mr. Kendall. “I will focus on the corporate, financial and strategic side while the team demonstrates MAPL’s commercial potential, so that any decision the Board makes is grounded in what the business is today and where it can realistically go.”

Article content

About Peter Kendall

Article content

Peter Kendall has more than twenty years of healthcare commercialization experience. His prior roles include President and Chief Commercialization Officer of AI/ML Innovations Inc. (CSE: AIML), Chief Executive Officer of Yurek Pharmacy Group, and National Director at Medisys Health Group, subsequently acquired by TELUS Health.

Article content

Terms of the Engagement

Article content

Under the Interim CEO Agreement, Mr. Kendall will provide services through Driftwood Family Holdings Inc. (“Driftwood”), a corporation incorporated under the laws of Ontario, Canada that is wholly-owned and controlled by Mr. Kendall.

Article content

In connection with the engagement, the Company has agreed to grant 4,000,000 restricted share units (“RSUs”) to Mr. Kendall, or at his direction and to the extent permitted under the Company’s omnibus security-based compensation plan and the rules of the Exchange, to Driftwood, with each RSU entitling the holder to receive one Class A Subordinate Voting Share of the Company upon vesting. The RSUs are scheduled to vest on the date that is 12 months following the effective date of the appointment.